Enveric Biosciences Advances Non-Hallucinogenic DMT Analog Drug With Promising Preclinical Results
Psychedelics biotech company Enveric Biosciences (NASDAQ:ENVB) completed preclinical pharmacokinetic (PK) studies for its leading drug candidate EB-003 aimed at treating depression and anxiety without causing hallucinations. EB-003 is a neuroplastic and non-hallucinogenic N, N-Dimethyltryptamine (DMT) analog drug candidate., such as ataxia or hyperthermia.
“Completion of these animal PK studies further supports our efforts to develop conveniently delivered, orally-available drugs with the potential to harness neuroplastic properties without inducing hallucinations,” stated Joseph Tucker, Ph.D., CEO of Enveric. “The additional data gained in these animal studies enhances our understanding of the preclinical profile of this drug candidate and brings us a step closer to finalizing the data package for the EB-003 Investigational New Drug (IND) application, which we anticipate submitting to the U.S. Food and …